CAR-HEMATOTOX模型:复发/难治性大B细胞淋巴瘤CAR-T相关血液学毒性预测模型
这项多中心分析纳入258例接受axi-cel或tisa-cel治疗的复发/难治性大B细胞淋巴瘤患者,研究造血重建模式并评估预测标志物。以至第+60天严重中性粒细胞减少持续时间为主要终点,建立并验证了包含造血储备和基线炎症指标的CAR-HEMATOTOX模型。该模型可区分严重中性粒细胞减少≥14天与<14天的患者,高评分与更长的中性粒细胞减少持续时间及更高的严重血小板减少和贫血发生率相关。
要点
- 72%患者出现深度中性粒细胞减少(ANC<100/µL),64%出现 prolonged neutropenia(≥21天)。
- CAR-HEMATOTOX模型包含血小板计数、血红蛋白、ANC、CRP和铁蛋白等指标。
- 高CAR-HEMATOTOX评分者中性粒细胞减少时间更长,严重血小板减少和贫血发生率更高。
核心结论
- CAR-HEMATOTOX模型可预测复发/难治性大B细胞淋巴瘤患者CAR-T后严重中性粒细胞减少的持续时间。
- 高评分与更长的中性粒细胞减少持续时间及更高的严重血小板减少和贫血发生率相关。
研究设计与样本
- 多中心分析,纳入258例接受axicabtagene ciloleucel或tisagenlecleucel治疗的复发/难治性大B细胞淋巴瘤患者。
- 训练队列58例,验证队列包括欧洲91例和美国109例。
- 主要终点为至第+60天严重中性粒细胞减少(ANC<500 cells/µL)的持续时间。
主要发现
- 72%患者出现ANC<100 cells/µL的深度中性粒细胞减少,64%患者出现持续21天或更长的中性粒细胞减少。
- 严重中性粒细胞减少(ANC<500 cells/µL)的中位持续时间为9天。
- 训练队列中,基线血小板减少(r=-0.43;P=.001)和高铁蛋白血症(r=0.54;P<.0001)与主要终点显著相关。
- 细胞因子释放综合征、免疫效应细胞相关神经毒性综合征的发生率与严重程度及峰值细胞因子水平与主要终点无关。
- 验证队列中区分严重中性粒细胞减少≥14天与<14天的汇总AUC为0.89,敏感性89%,特异性68%。
关键数值与推荐
- CAR-HEMATOTOX模型包含造血储备标志物(如血小板计数、血红蛋白、ANC)和基线炎症标志物(如C反应蛋白、铁蛋白)。
- 验证队列汇总区分严重中性粒细胞减少≥14天与<14天的AUC为0.89,敏感性89%,特异性68%。
临床怎么用
- 可用于CAR-T治疗前评估患者血液学毒性风险,辅助风险适应性管理。
- 高评分患者可能需要更密切的血液学监测和支持治疗。
局限性
- 训练队列样本量较小(n=58)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell-related adverse event and remains poorly understood. In this multicenter analysis, we studied patterns of hematopoietic reconstitution and evaluated potential predictive markers in 258 patients receiving axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) for relapsed/refractory large B-cell lymphoma. We observed profound (absolute neutrophil count [ANC] <100 cells per µL) neutropenia in 72% of patients and prolonged (21 days or longer) neutropenia in 64% of patients. The median duration of severe neutropenia (ANC < 500 cells per µL) was 9 days. We aimed to identify predictive biomarkers of hematotoxicity using the duration of severe neutropenia until day +60 as the primary end point. In the training cohort (n = 58), we observed a significant correlation with baseline thrombocytopenia (r = -0.43; P = .001) and hyperferritinemia (r = 0.54; P < .0001) on univariate and multivariate analysis. Incidence and severity of cytokine-release syndrome, immune effector cell-associated neurotoxicity syndrome, and peak cytokine levels were not associated with the primary end point. We created the CAR-HEMATOTOX model, which included markers associated with hematopoietic reserve (eg, platelet count, hemoglobin, and ANC) and baseline inflammation (eg, C-reactive protein and ferritin). This model was validated in independent cohorts, one from Europe (n = 91) and one from the United States (n = 109) and discriminated patients with severe neutropenia ≥14 days to <14 days (pooled validation: area under the curve, 0.89; sensitivity, 89%; specificity, 68%). A high CAR-HEMATOTOX score resulted in a longer duration of neutropenia (12 vs 5.5 days; P < .001) and a higher incidence of severe thrombocytopenia (87% vs 34%; P < .001) and anemia (96% vs 40%; P < .001). The score implicates bone marrow reserve and inflammation prior to CAR T-cell therapy as key features associated with delayed cytopenia and will be useful for risk-adapted management of hematotoxicity.
引用
- Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021. PMID: 34166502. doi:10.1182/blood.2020010543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。